- Home
- SNCY vs NBTX Comparison
SNCY vs NBTX Comparison
Compare SNCY & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | NBTX |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 1.0B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SNCY | NBTX |
|---|---|---|
| Price | $17.96 | $32.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $19.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 574.4K | 41.4K |
| Earning Date | 04-30-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $1,126,769,000.00 | N/A |
| Revenue This Year | $11.29 | $59.10 |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $8.10 | $3.12 |
| 52 Week High | $22.29 | $41.89 |
Technical Indicators
Market Signals| Indicator | SNCY | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 52.30 |
| Support Level | $16.93 | $20.11 |
| Resistance Level | $17.93 | $34.66 |
| Average True Range (ATR) | 0.69 | 1.91 |
| MACD | 0.21 | -0.16 |
| Stochastic Oscillator | 73.92 | 47.92 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.